Journal: medRxiv
Article Title: Tryptophan pathway metabotypes associate with disease activity and immune-metabolic dysfunction in inflammatory bowel disease
doi: 10.64898/2026.05.03.26352309
Figure Lengend Snippet: (A) Odds ratios show enrichment of clinical features across metabotypes. (B) Survival curves for biologic initiation, novel corticosteroid use, IBD-related hospitalization, and IBD-related surgery by cluster (Cox models adjusted for age and sex). (C) High Quin showed the highest proportion of aggressive disease in the IBSEN III cohort. (D) Top 15 observed metabotype transitions from baseline, week 2 and week 14 for patients with metabolomics data at each of the three time points. (E) Final cluster assignment at week 14 and its relationship with therapy response. A,B: MSCCR; C: IBSEN III; D,E: Discovery cohort.
Article Snippet: Samples from MSCCR were used for semi-quantitative untargeted metabolomics analysis performed by Metabolon, Inc. (Research Triangle Park, North Carolina, United States) [ , ].
Techniques: